France to China CAR-T Therapy: Access Trials Unavailable in Europe

by China Medical Services

The Problem: Europe’s CAR-T Pipeline Leaves Patients Waiting

France has approved six CAR-T therapies. All of them target CD19 or BCMA markers in hematologic cancers. If your diagnosis falls outside those narrow targets — gastric cancer, pancreatic cancer, glioblastoma, certain sarcomas — you are out of approved options. The European Medicines Agency has not authorized a single CAR-T product for solid tumors. Meanwhile, China’s Center for Drug Evaluation has cleared more than 100 CAR-T investigational new drug applications. The clinical reality is stark: patients with relapsed or refractory disease who exhaust European treatment protocols face a window that closes fast. Traveling to access trials is not a luxury decision. It is a survival calculation.

Wait times compound the pressure. A patient in Lyon or Marseille who qualifies for an academic trial may wait six to ten weeks for enrollment screening, cell collection scheduling, and manufacturing slot availability. Some trials cap enrollment at twelve to twenty patients per year. The math is unforgiving. China’s trial infrastructure operates at a different scale — single centers routinely enroll that many patients in a quarter. For someone watching a rising tumor marker, those weeks matter.

Who We Are

We are not a hospital. We do not provide medical treatment, make clinical recommendations, or promise outcomes. We are your logistical architects — a team based in China that connects international patients with the country’s top-tier hospitals. Our database covers 340+ top-ranked hospitals across 37 cities, representing the top 5% of China’s 35,000+ medical institutions as ranked by Fudan University’s hospital evaluation and JCI accreditation. We handle hospital matching, appointment coordination through official international medical center channels, bilingual medical companion services, and visa guidance. We do not sell access. We solve the structural barriers that make China’s healthcare system impenetrable to someone who does not speak the language or understand the administrative pathways.

Why China’s CAR-T Ecosystem Delivers Options Europe Cannot Match

Trial Volume and Target Diversity

As of early 2025, China accounts for more registered CAR-T clinical trials than any other country. The numbers are not close. Over 500 studies are active or recruiting across mainland China, compared to approximately 280 in the United States and fewer than 80 across all EU member states combined. The critical difference is target breadth. Chinese trials are aggressively pursuing CLDN18.2 in gastric cancer, GPC3 in hepatocellular carcinoma, EGFRvIII in glioblastoma, and mesothelin in pancreatic and ovarian cancers — all targets with essentially zero approved CAR-T options in Europe. A patient with CLDN18.2-positive advanced gastric adenocarcinoma who has progressed through standard chemotherapy and immunotherapy in France has no CAR-T pathway at home. In China, multiple Phase I and Phase II trials are actively recruiting for exactly that profile. This is not theoretical. It is a pipeline that exists today.

The regulatory environment explains part of this. China’s National Medical Products Administration implemented expedited review pathways for cell and gene therapies in 2021, allowing academic medical centers and biotech firms to move from preclinical data to first-in-human dosing faster than EMA timelines permit. This acceleration carries risk — early-phase trials have less mature safety data — but for patients with progressing disease and no alternatives, the risk-benefit calculus shifts substantially.

Best CAR-T Cell Therapy Hospitals China for International Patients

Several centers have built dedicated international patient offices precisely because demand from overseas is growing. Peking University Cancer Hospital runs one of the largest gastrointestinal oncology CAR-T programs globally, with particular depth in CLDN18.2-targeted constructs. Ruijin Hospital in Shanghai, affiliated with Shanghai Jiao Tong University School of Medicine, has published extensively on BCMA-directed CAR-T for multiple myeloma and maintains an international medical center with English-speaking coordination staff. The Affiliated Cancer Hospital of Zhengzhou University handles high volumes of hematologic malignancy trials and has treated patients from the Middle East and Southeast Asia. Tongji Hospital in Wuhan operates a GMP-certified cell manufacturing facility on-site, which compresses vein-to-vein time — the period between cell collection and infusion — to as little as ten days for certain protocols. In Europe, that interval routinely stretches to three or four weeks, during which bridging chemotherapy may be necessary.

These hospitals are not boutique clinics. They are massive academic medical centers. Ruijin Hospital alone records over 40,000 inpatient discharges annually. The scale means clinical teams see rare presentations and manage complex cytokine release syndrome cases with frequency that smaller European centers simply do not accumulate. Volume builds competence. That principle holds across surgical oncology, and it holds in cell therapy management.

Car-T Therapy Cost China: The Structural Price Gap

The commercial CAR-T products approved in China — Yescarta, Carteyva, and JWCAR029 among them — are priced significantly below their European equivalents. A single infusion of Yescarta in France costs approximately $373,000 at list price. The same product in China lists around $120,000. Carteyva, a domestic CD19-directed CAR-T, is priced near $70,000. These are not minor differences. They are order-of-magnitude gaps that change the financial feasibility calculation for families who are self-funding treatment.

Why the gap? It is not about lower quality. Manufacturing cost structures in China benefit from domestic vector production, lower labor costs in cleanroom operations, and higher production volumes that amortize facility overhead across more batches. Hospitals also operate with leaner administrative cost layers. A bone marrow transplant unit in Shanghai runs at roughly one-fifth the per-diem cost of a comparable unit in Paris, driven primarily by nursing labor economics and pharmaceutical pricing negotiated through national volume-based procurement. The clinical protocols — apheresis, lymphodepletion, infusion, CRS monitoring — are substantively identical to international standards. Many Chinese CAR-T investigators trained at MD Anderson, Memorial Sloan Kettering, or European academic centers before returning to build programs in China.

*Trial participation costs vary widely. Many Chinese trials cover the investigational CAR-T product and protocol-mandated procedures; patients typically bear hospitalization, travel, and supportive care costs. Always confirm cost allocation with the specific trial sponsor before committing.

How to Access China CAR-T Clinical Trials from France

The pathway from a clinic in France to a treatment chair in Shanghai involves five discrete steps. Each has friction points. Understanding them before you commit saves weeks of wasted effort.

Step one is medical record preparation. Chinese hospitals require a complete, translated clinical summary: pathology reports with immunohistochemistry or sequencing results, imaging studies on CD or DICOM format, treatment history with dates and responses, and current performance status. Translation must be medically precise — Google Translate will not suffice for a flow cytometry report or a next-generation sequencing panel. Our team handles certified medical translation as part of the coordination process.

Step two is hospital and trial matching. This is where most independent attempts break down. ClinicalTrials.gov captures only a fraction of Chinese CAR-T studies. Many trials register exclusively on the Chinese Clinical Trial Registry, which operates in Mandarin. We cross-reference both databases and directly contact hospital international medical centers to confirm active recruitment status, specific inclusion criteria, and slot availability. A trial listed as “recruiting” online may have already filled its current cohort. We verify before you book a flight.

Step three is the remote pre-evaluation. Most hospitals will review translated records and provide a preliminary eligibility assessment before requiring travel. This typically takes five to ten business days. Some centers offer formal video consultations with the principal investigator or a senior attending on the trial team. Our video consultation coordination arranges these sessions with full interpretation support. The fee for this service — typically $500 to $800 for a top-specialist video consultation — is fully credited toward on-the-ground coordination if you proceed to treatment within 90 days. You are not risking sunk costs by exploring your options.

Step four is the visa and travel arrangement. Medical treatment in China requires an S2 visa with the specific purpose annotated. The supporting documents include a hospital invitation letter confirming your appointment or trial enrollment, proof of accommodation, and passport validity exceeding six months. Family members accompanying you apply for their own S2 visas. This is not a tourist visa process. Embassy officers scrutinize medical visa applications carefully. Incomplete documentation results in rejection with no expedited appeal. We provide the document checklist and work directly with the hospital to secure the official invitation letter in the format consulates expect.

Step five is arrival, enrollment screening, and treatment initiation. You will undergo fresh baseline assessments — labs, imaging, possibly repeat biopsy — to confirm eligibility per protocol criteria. Then apheresis for T-cell collection, a waiting period for manufacturing, lymphodepleting chemotherapy, and finally CAR-T infusion with inpatient monitoring. The entire process from landing in China to infusion day typically spans four to six weeks. A bilingual medical companion accompanies you through every appointment, translating in real time, handling registration and payment queues, and ensuring nothing gets lost between departments. Chinese public hospitals see 10,000 outpatient visits daily at major centers. Without a guide, the physical navigation alone is exhausting.

Can I Get CAR-T Therapy in China Not Available in Europe?

The short answer is yes — but through clinical trials, not commercial prescriptions. CAR-T products approved in China that lack EMA authorization cannot simply be prescribed to international patients as standard care. You enroll in a clinical trial as a research participant, or you access the therapy through a hospital’s expanded access or named-patient program if available. This distinction matters for several reasons. Trial protocols specify exact eligibility criteria. If your prior lines of therapy, organ function, or tumor marker profile do not match the protocol, you cannot enroll — no exceptions. Expanded access programs exist at some major centers but are not universal. Our role is to identify which specific trials or programs match your clinical situation and confirm availability before you incur travel costs.

Also worth understanding: China’s hospital system does not operate on a direct-booking model for international patients seeking trials. You cannot email a hospital and receive a confirmed enrollment slot. The process requires a formal medical record review, a determination by the principal investigator’s team, and coordination through the hospital’s international medical center or clinical research office. Attempting this independently from France, in English or French, with no Mandarin capability and no understanding of the administrative structure, is functionally impossible. That is not gatekeeping. It is an honest description of how the system works.

What You Need to Know Before Going Alone

• Visa requirements are strict: Medical treatment requires an S2 visa with a hospital invitation letter. Tourist visas explicitly prohibit medical treatment. If you arrive on an L visa and present for a scheduled clinical trial screening, you risk denial at the hospital registration desk. The consular process takes two to four weeks from document submission to passport return.
• Payment systems do not accept foreign insurance directly: Chinese public hospitals require prepayment — a deposit at registration, drawn down as charges accrue. International credit cards are accepted at international medical centers but not at general hospital cashiers. Wire transfers take three to five business days to clear. You need liquid funds accessible in China on day one. Private international hospitals like United Family can direct-bill some insurers; public hospital international departments generally cannot.
• Medical records must be translated, not just linguistically but diagnostically: A pathology report from Institut Gustave Roussy uses different formatting, grading conventions, and abbreviation standards than what a Chinese oncologist expects to see. Machine translation garbles immunohistochemistry markers and genetic variant nomenclature. Certified medical translation is a hard requirement, not a nice-to-have.
• Public hospital general outpatient departments cannot be pre-booked from overseas: You cannot email a public hospital to reserve a general outpatient slot. The international medical center or VIP clinic is the only channel that accepts overseas pre-booking. This channel costs more — typically 1.5 to 2 times the standard consultation fee — and provides English-speaking coordination, priority scheduling, and a dedicated waiting area. It is not a luxury upsell. It is the only functional pathway for an international patient who does not speak Mandarin and does not have a Chinese national ID number for the hospital’s online registration system.

How We Help You Navigate This

These barriers exist for structural reasons, not because anyone is trying to exclude foreign patients. China’s healthcare system is designed for a domestic population of 1.4 billion people. International patient services are a small, specialized overlay on top of that enormous apparatus. Our entire operation exists to bridge the gap between how the system works and what an international patient needs.

Before you travel, we handle hospital selection based on your specific diagnosis and molecular profile, not generic rankings. A hospital that is excellent for BCMA-directed myeloma CAR-T may have no active gastric cancer trials. We verify active recruitment, confirm inclusion criteria against your records, arrange remote pre-evaluation with the clinical team, coordinate certified medical translation, and secure the hospital invitation letter for your visa application. We also advise on accommodation — proximity to the hospital matters enormously when you need daily monitoring for two weeks post-infusion.

During your treatment, a bilingual medical companion accompanies you to every appointment. This person handles registration queues, payment processing, pharmacy pickups, and real-time interpretation during consultations. They also serve as your cultural translator — explaining why a doctor responded a certain way, what a particular administrative delay means, and how to interpret clinical communication styles that differ from French medical culture. Chinese physicians tend to communicate more directly and with less emphasis on shared decision-making than French patients may expect. Understanding this dynamic in advance reduces friction and anxiety.

After discharge, we coordinate follow-up scheduling, medication procurement for your return to France, and secure transfer of medical records and imaging back to your home oncologist. CAR-T follow-up extends for months. Your French hematologist or oncologist needs complete documentation of the product administered, the CRS grade and management, the engraftment data, and the surveillance schedule. We ensure that handoff is thorough.

Frequently Asked Questions